Nov 3, 2022 Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update Learn More
Oct 25, 2022 Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules Learn More
Oct 21, 2022 Cellectar Biosciences Announces Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules Learn More
Sep 22, 2022 Cellectar Awarded $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors Learn More